Financial Performance - Operating revenue for the period reached CNY 225,662,001.09, a 35.14% increase year-on-year[8] - Net profit attributable to shareholders was CNY 116,103,579.65, reflecting a 35.96% increase compared to the same period last year[8] - Basic earnings per share rose by 35.93% to CNY 0.2217[8] - Total operating revenue for the current period reached ¥225,662,001.09, a 35% increase from ¥166,984,187.12 in the previous period[56] - Net profit for the current period was ¥114,131,251.78, representing a 34% increase compared to ¥85,187,635.57 in the previous period[59] - The total profit for the current period was ¥286,686,911.88, compared to ¥222,337,915.10 in the previous period, showing a growth of 28.9%[73] - The total comprehensive income for the current period was ¥242,829,112.44, compared to ¥189,144,518.54 in the previous period, reflecting a 28.4% increase[73] Assets and Liabilities - Total assets increased by 29.90% to CNY 1,374,187,040.89 compared to the end of the previous year[8] - Total liabilities increased to ¥72,157,419.36 from ¥62,471,999.59, marking a rise of about 11.5% year-over-year[42] - Total equity attributable to shareholders rose to ¥1,219,153,365.50 from ¥969,517,290.46, showing an increase of approximately 25.7%[45] - Total current assets increased to ¥1,027,821,517.98 from ¥781,658,393.23, representing a growth of approximately 31.5% year-over-year[39] - Non-current assets totaled ¥346,365,522.91, up from ¥276,234,115.45, indicating a year-over-year increase of about 25.4%[39] Cash Flow - Cash flow from operating activities for the year-to-date was CNY 157,551,183.19, an increase of 19.01%[8] - Net cash flow from financing activities increased by 128,420,000.00 yuan, a rise of 198.67%, primarily due to increased cash from minority shareholders' investments in subsidiaries[24] - Cash and cash equivalents increased to ¥394,333,616.27 from ¥317,219,365.02, representing a growth of about 24.3%[46] - Cash flow from operating activities generated ¥157,551,183.19, compared to ¥132,382,655.68 in the same period last year[81] - The company received cash inflows from investment activities totaling ¥264,912,984.10, down from ¥647,084,171.25 in the previous year[82] Shareholder Information - The total number of shareholders at the end of the reporting period was 14,676[12] - The largest shareholder, Zhejiang Wo Wu Management Consulting Co., Ltd., holds 38.86% of the shares[12] Research and Development - R&D expenses surged by 17,120,795.59 yuan, a significant increase of 189.47%, due to higher material consumption and salaries in the stem cell subsidiary[23] - Research and development expenses rose significantly to ¥12,102,332.46, up from ¥3,253,633.11 in the previous period, indicating a focus on innovation[56] - Research and development expenses for the current period amounted to ¥26,156,958.32, significantly higher than ¥9,036,162.73 in the previous period, marking a 189.5% increase[69] Government Support - The company received government subsidies amounting to CNY 3,505,769.64 during the reporting period[8] Other Financial Metrics - The weighted average return on equity was 10.00%, a slight increase of 0.33%[8] - The company reported a financial asset impairment loss of ¥3,368,948.21, compared to a loss of ¥2,192,490.79 in the previous period[63] - Other comprehensive income after tax for the current period was ¥8,154.10, down from ¥13,968.79 in the previous period[62] Future Outlook - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[61]

Financial Performance - Total operating revenue for the first half of 2019 was CNY 274,337,272.82, representing a 25.43% increase compared to CNY 218,709,503.59 in the same period last year[27]. - Net profit attributable to shareholders was CNY 130,478,340.23, up 25.53% from CNY 103,940,262.61 year-on-year[27]. - Net profit after deducting non-recurring gains and losses reached CNY 127,500,058.62, reflecting a 28.65% increase from CNY 99,102,541.29 in the previous year[27]. - Net cash flow from operating activities was CNY 103,539,335.95, an increase of 24.28% compared to CNY 83,310,857.99 in the same period last year[27]. - Basic earnings per share were CNY 0.2492, up 25.54% from CNY 0.1985 in the previous year[27]. - Operating profit reached 149.66 million CNY, up 23.06% compared to the previous year[38]. - The company achieved operating revenue of 274.34 million CNY, a year-on-year increase of 25.43%[55]. - Operating profit reached RMB 149.66 million, reflecting a growth of 23.06% compared to the previous year[55]. - Net profit attributable to shareholders was RMB 130.48 million, marking a 25.53% increase year-on-year[55]. - The company reported a net profit for the first half of 2019 of ¥128,688,434.05, up 23.8% from ¥103,940,262.61 in the first half of 2018[194]. - Basic earnings per share for the first half of 2019 were ¥0.2492, compared to ¥0.1985 in the same period of 2018, reflecting a growth of 25.5%[198]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,238,408,366.37, a 17.06% increase from CNY 1,057,892,508.68 at the end of the previous year[27]. - Net assets attributable to shareholders reached CNY 1,103,041,631.75, reflecting a 13.77% increase from CNY 969,517,290.46 at the end of the previous year[27]. - Cash and cash equivalents at the end of the reporting period amounted to ¥673,869,551.68, representing 54.41% of total assets, an increase of 12.98% compared to the previous year[60]. - Accounts receivable stood at ¥134,127,655.85, accounting for 10.83% of total assets, a decrease of 2.48% from the same period last year[60]. - Inventory increased to ¥29,229,412.85, which is 2.36% of total assets, up by 0.41% year-on-year[60]. - Fixed assets totaled ¥126,292,997.10, making up 10.20% of total assets, a decrease of 3.25% compared to the previous year[60]. - The total amount of funds raised was ¥192,384,093.71, with cumulative investment of ¥89,286,578.34 as of June 30, 2019[67]. - The company’s total equity increased to ¥1,039,271,221.65, up from ¥978,568,462.57 in the previous year[191]. - Total liabilities decreased to ¥50,518,150.72 from ¥62,471,999.59, a reduction of about 19.14%[181]. Research and Development - Research and development expenses surged by 130.52% to RMB 27.42 million, driven by ongoing and new projects[55]. - The company completed a Phase III clinical trial for "Artemisia annua powder drops" for allergic rhinitis, with registration application accepted in April 2019[48]. - The company is advancing multiple allergy treatment products, including nine new skin prick test products currently in Phase I clinical trials[49]. - The company has committed to investing 100 million RMB in R&D for new technologies over the next two years[105]. Market and Product Development - The company is focusing on expanding its product line and market presence in the field of sublingual immunotherapy[38]. - The company’s main product, the dust mite drop, maintains the highest market share in the dust mite desensitization drug market since 2012[42]. - The company has established a professional academic marketing team to enhance product promotion across key regions in China[38]. - The company is engaged in the development of new drugs for allergic diseases, which involves long and unpredictable cycles, posing various risks[7]. - The company is expanding its market presence in Southeast Asia, targeting a 25% market share by 2021[105]. - A strategic acquisition of a local competitor is anticipated to enhance the company's product offerings and increase market penetration[105]. Risks and Challenges - The company faces risks related to the concentration of its main product, "Dust Mite Drops," which constitutes a significant portion of its revenue[6]. - The company is facing industry policy risks due to ongoing reforms in the national healthcare system, which may impact the pharmaceutical operating environment[88]. - The company faces risks from price reductions in drug tenders, which may impact long-term sales and performance due to measures like medical insurance cost control and secondary negotiations[89]. - High product gross margins may be affected by changes in centralized procurement prices and rising costs of raw materials and labor, introducing uncertainty in sustained performance growth[89]. - The company is engaged in the development of new drugs for allergic diseases and anti-aging, which involves lengthy and costly processes with unpredictable risks[90]. Shareholder Information - The total number of shares increased from 290,880,000 to 523,584,000, with a cash dividend of RMB 72,720,000 distributed to shareholders[139]. - Basic earnings per share rose to 0.80, compared to 0.44 in the previous period[143]. - The diluted earnings per share also increased to 0.80, up from 0.44[143]. - The net asset per share attributable to ordinary shareholders increased to 3.33, compared to 1.85 previously[143]. - The company plans to distribute 8 bonus shares for every 10 shares held, totaling 232,704,000 shares[139]. - The largest shareholder, Zhejiang Wo Wu Management Consulting Co., Ltd., holds 38.86% of the shares[144]. Compliance and Governance - The company has maintained compliance with all regulatory commitments, with no violations reported during the reporting period[106]. - The company has not reported any significant changes in the use of raised funds during the reporting period[67]. - The company has not engaged in derivative investments or entrusted loans during the reporting period[82][83]. - The company has not sold any significant assets or equity during the reporting period[84][85]. - The company has no significant litigation or arbitration matters during the reporting period[110]. - There were no major related party transactions or significant contracts during the reporting period[115][126].

Financial Performance - Total revenue for Q1 2019 was ¥138,084,397.75, representing a 29.13% increase compared to ¥106,934,012.73 in the same period last year[8] - Net profit attributable to shareholders was ¥66,137,709.53, up 27.30% from ¥51,954,370.06 year-over-year[8] - Net profit excluding non-recurring gains and losses reached ¥64,976,342.53, reflecting a 32.47% increase from ¥49,050,392.90 in the previous year[8] - Basic earnings per share for the quarter was ¥0.2274, a 27.32% increase compared to ¥0.1786 in the same period last year[8] - Total operating revenue for Q1 2019 reached ¥138,084,397.75, an increase of 29.4% compared to ¥106,934,012.73 in Q1 2018[73] - Operating profit for Q1 2019 was ¥77,034,222.27, compared to ¥60,691,260.56 in Q1 2018, representing a growth of 27.0%[73] - The net profit for the current period was ¥67,539,752.12, representing a 27.7% increase from ¥52,953,002.42 in the previous period[82] - The total profit for the current period was ¥79,091,801.55, up from ¥62,151,151.28, marking a growth of 27.3%[80] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥1,248,239,738.75, a 17.99% increase from ¥1,057,892,508.68 at the end of the previous year[8] - The company's total assets reached 1.2482 billion yuan, up from 1.0579 billion yuan at the end of 2018[56] - The total liabilities decreased to ¥50,8518 million yuan from ¥62,4720 million yuan year-over-year[59] - The company's total liabilities decreased to ¥46,936,747.38 in Q1 2019 from ¥58,306,981.11 in Q4 2018, a reduction of 19.5%[69] - Shareholders' equity totaled CNY 995,420,509.09, with CNY 969,517,290.46 attributable to the parent company[100] Cash Flow - The company reported a net cash flow from operating activities of ¥48,377,037.23, down 15.75% from ¥57,417,598.08 in the same period last year[8] - Cash and cash equivalents increased by 270,370,874.73 yuan, up 58.77% compared to the end of the previous year, mainly due to minority shareholders' capital increase and the redemption of bank wealth management products[22] - The cash flow from operating activities was ¥142,163,309.05, an increase from ¥111,284,662.25 in the previous period, reflecting a growth of 27.7%[84] - The net cash flow from investment activities was CNY 86,452,902.72, significantly higher than CNY 25,993,366.99 in the previous period, reflecting an increase of 232.5%[94] Expenses - Operating costs decreased by 2,175,766.36 yuan, a reduction of 30.70%, primarily due to high costs in the previous year from reduced semi-finished product output[23] - Sales expenses increased by 15,175,435.52 yuan, an increase of 45.67%, driven by a rise in the number of sales personnel and increased marketing expenses[23] - R&D expenses rose by 3,928,044.03 yuan, an increase of 156.41%, attributed to higher salaries and material costs in the stem cell subsidiary[23] - Research and development expenses increased significantly to ¥6,439,340.39 in Q1 2019, up from ¥2,511,296.36 in Q1 2018, marking a rise of 156.5%[73] Shareholder Information - The top shareholder, Zhejiang Wawu Management Consulting Co., Ltd., holds 38.86% of the shares, totaling 113,030,073 shares[12] - The total number of common shareholders at the end of the reporting period was 10,040[12] Projects and Investments - The company completed Phase III clinical trials for the Artemisia annua pollen drop product, enhancing its market competitiveness[27] - The project "Marketing Network Expansion and Information Technology Construction" did not meet planned progress due to slower than expected acquisition of office properties[39] - The company has decided to terminate the "Marketing Network Expansion and Information Technology Construction" project and will permanently supplement remaining raised funds into working capital[39] - The annual production capacity of the dust mite drop agent technology transformation project is 300 million units, with an investment completion rate of 97.92%[41] - The allergen research center technology transformation project has an investment completion rate of 79.36%[41] Regulatory and Compliance - The company received drug registration approval and new drug certificate for the "House Dust Mite Skin Prick Diagnostic Kit" on March 26, 2019[32] - The company has made commitments regarding share reduction and has not fulfilled them within the specified time[35] - The company reported no violations regarding external guarantees or non-operating fund occupation by controlling shareholders during the reporting period[48][49]

Financial Performance - The company's operating revenue for 2018 was ¥500,744,692.07, representing a 29.87% increase compared to ¥385,576,841.66 in 2017[22] - The net profit attributable to shareholders for 2018 was ¥232,884,097.51, a 25.14% increase from ¥186,103,945.40 in 2017[22] - The net profit after deducting non-recurring gains and losses was ¥224,864,128.66, up 27.33% from ¥176,604,724.34 in 2017[22] - The net cash flow from operating activities was ¥206,452,525.31, reflecting a 29.73% increase compared to ¥159,134,139.23 in 2017[22] - The total assets at the end of 2018 were ¥1,057,892,508.68, a 24.71% increase from ¥848,311,200.92 at the end of 2017[22] - The net assets attributable to shareholders at the end of 2018 were ¥969,517,290.46, which is a 21.00% increase from ¥801,257,929.88 at the end of 2017[22] - The basic earnings per share for 2018 was ¥0.8006, up 25.13% from ¥0.6398 in 2017[22] - The diluted earnings per share for 2018 was also ¥0.8006, reflecting the same 25.13% increase from ¥0.6398 in 2017[22] - The weighted average return on equity for 2018 was 26.63%, an increase of 1.08% from 25.55% in 2017[22] Research and Development - The company invested 38.62 million yuan in R&D, accounting for 7.71% of operating revenue[42] - The company holds 13 valid domestic invention patents and several international patents, indicating strong R&D capabilities[42] - Research and development expenses rose to CNY 134.79 million, a significant increase of 75.01% due to new stem cell research projects[47] - The company is actively expanding its product line in the allergy treatment sector, with several products in various stages of clinical trials[51] Product and Market Performance - The company’s main product, the dust mite drop, maintains the highest market share in the dust mite desensitization drug market since 2012[41] - Revenue from pharmaceutical manufacturing was ¥498,413,975.94, accounting for 99.53% of total revenue, with a year-on-year growth of 30.50%[55] - The sales volume of dust mite drops increased by 31.82% year-on-year, with production volume rising by 45.51% and inventory volume by 54.69%[61] - The company’s gross profit margin for pharmaceutical manufacturing was 94.62%, with a year-on-year increase of 30.50%[60] Cash Flow and Investments - Cash and cash equivalents rose to 274.23 million yuan, an increase of 147.58% primarily from the redemption of bank wealth management products[40] - The company's cash flow from investment activities turned positive with a net inflow of ¥132,391,291.78, a significant improvement from a net outflow in the previous year[75] - The net increase in cash and cash equivalents surged by 652.22% to ¥274,228,878.88, attributed to higher cash flows from both investment and operating activities[75] Shareholder Returns and Dividends - The company plans to distribute a cash dividend of ¥2.50 per 10 shares and issue 8 bonus shares for every 10 shares held[6] - The cash dividend represents 31.23% of the net profit attributable to ordinary shareholders for 2018, which was RMB 232,884,097.51[113] - The proposed profit distribution plan is subject to approval at the 2018 annual shareholders' meeting[111] Corporate Governance and Compliance - The company has committed to not transferring or entrusting the management of its shares for 36 months post-IPO, with a maximum annual transfer of 25% of total shares held during the tenure of the individual or their affiliates[116] - The company has maintained compliance with commitments regarding avoiding competition and related transactions during the reporting period[116] - The company has made commitments regarding the accuracy and completeness of its prospectus, ensuring investor protection against losses due to false statements or omissions[121] Subsidiaries and Corporate Structure - The company established Shanghai Iwu Stem Cell Technology Co., Ltd. with an investment of 30 million RMB[165] - The company has established three new subsidiaries in 2018, including Shanghai Iwu Stem Cell Technology Co., Ltd. with a registered capital of RMB 15 million and Zhejiang Iwu Stem Cell Technology Co., Ltd. with RMB 3 million[135] - The company has canceled its subsidiary WOLWOPHARMA (MALAYSIA) SDN.BHD., which was involved in the import, manufacturing, and retail of pharmaceuticals, effective June 2018[134] Management and Shareholding - The actual controller of the company is Hu Gengxi, who is also the chairman and general manager[185] - The company has a diverse board with members holding advanced degrees and extensive experience in biotechnology and finance[196][198] - The total number of shares held by the board members, supervisors, and senior management at the beginning of the period were 24,451,494 shares, which increased to 43,764,309 shares by the end of the period, reflecting a net increase of 19,561,195 shares[192]

Financial Performance - Net profit attributable to shareholders reached ¥85,398,504.94, a growth of 22.42% year-on-year[9] - Operating revenue for the period was ¥166,984,187.12, reflecting a 29.96% increase compared to the same period last year[9] - The net profit excluding non-recurring gains and losses was ¥83,249,054.80, a 23.42% increase year-on-year[9] - The company reported a basic earnings per share of ¥0.2936, reflecting a 22.44% increase compared to the same period last year[9] - The net profit for the current period was ¥87,560,739.67, representing a growth of 22.8% from ¥71,274,098.17 in the same period last year[44] - The company reported a total profit of ¥226,352,867.92 for the current period, which is an increase from ¥177,907,450.19 in the previous period, marking a growth of around 27.2%[52] Assets and Liabilities - Total assets increased to ¥1,001,923,973.03, up 18.11% from the previous year[9] - Total liabilities rose to ¥48,944,314.65 from ¥47,252,091.52, a slight increase of about 4%[36] - The company's equity attributable to shareholders increased to ¥931,898,069.95 from ¥803,361,735.71, reflecting a growth of approximately 16%[37] - The total assets amounted to ¥1,001,923,973.03, compared to ¥848,311,200.92 at the beginning of the year[32] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥132,382,655.68, up 12.08%[9] - The net increase in cash and cash equivalents was ¥302,295,108.83, up 510.07% year-on-year, mainly due to the increase in net cash flow from investing activities[21] - The cash flow from operating activities generated a net amount of ¥132,382,655.68, up from ¥118,117,953.32 in the previous period, reflecting an increase of approximately 12.5%[53] - The company's total cash flow from financing activities resulted in a net outflow of -¥64,640,000.00, compared to -¥40,400,000.00 in the previous period, reflecting a larger outflow[55] Investments and Expenses - Research and development expenses for the quarter were ¥3,253,633.11, up from ¥1,956,363.57, showing an increase of approximately 66%[38] - Research and development expenses rose to ¥3,214,875.61, up 64.2% from ¥1,956,363.57 in the previous period, indicating a strong focus on innovation[43] - The company recorded investment income of ¥6,589,202.67, up from ¥5,407,162.92, which is an increase of approximately 21.8%[51] - The company reported an investment income of ¥1,365,391.58, down from ¥2,441,884.21, reflecting a decrease of 44%[44] Shareholder Equity and Dividends - The company's share capital increased by ¥129,280,000.00, an 80.00% rise due to the capital reserve conversion plan[18] - The company paid out 64,640,000.00 CNY in dividends and interest, which is an increase from 40,400,000.00 CNY in the previous period, reflecting a rise of 60%[59] Market and Growth Strategy - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[49] - Operating revenue increased by ¥92,071,310.57, a growth of 31.36% year-on-year, mainly driven by the rising sales volume of the company's main products as the desensitization treatment market expands[20] Miscellaneous - There were no violations regarding external guarantees or non-operating fund occupation by controlling shareholders during the reporting period[25][26] - The third quarter report was not audited, which may affect the reliability of the financial data presented[60]

Financial Performance - Total revenue for the reporting period reached ¥218,709,503.59, representing a 32.44% increase compared to ¥165,132,855.77 in the same period last year[22] - Net profit attributable to shareholders was ¥103,940,262.61, up 32.02% from ¥78,730,064.47 year-on-year[22] - The net cash flow from operating activities increased by 12.73% to ¥83,310,857.99, compared to ¥73,905,603.31 in the previous year[22] - Basic earnings per share rose to ¥0.3573, reflecting a 31.99% increase from ¥0.2707 in the same period last year[22] - Operating profit reached 121.61 million yuan, an increase of 32.42% compared to the previous year[30] - The company achieved a revenue of 218.71 million yuan, representing a year-on-year growth of 32.44%[30] - The company reported a net profit attributable to shareholders for 2017 between RMB 180.88 million and RMB 193.80 million, representing a year-on-year growth of 40% to 50%[94] - For Q1 2018, the net profit attributable to shareholders is projected to be between RMB 47.76 million and RMB 55.40 million, indicating a year-on-year growth of 25% to 45%[94] Assets and Liabilities - The company's total assets at the end of the reporting period were ¥891,041,645.90, a 5.04% increase from ¥848,311,200.92 at the end of the previous year[22] - The net assets attributable to shareholders increased by 4.91% to ¥840,560,844.06, compared to ¥801,257,929.88 at the end of the previous year[22] - Total current assets increased to ¥684,961,188.16 from ¥656,497,226.95, reflecting a growth of 4.5%[120] - Total liabilities rose to ¥50,480,801.84 from ¥47,053,271.04, an increase of 5.2%[121] - Owner's equity increased to ¥840,560,844.06 from ¥801,257,929.88, reflecting a growth of 4.9%[122] Cash Flow - Cash and cash equivalents increased by 298.68% to CNY 183.33 million, primarily due to the redemption of bank financial products[40] - The company reported a net cash inflow from investment activities of CNY 515,537,239.75, compared to CNY 379,372,780.14 in the previous year[136] - The net increase in cash and cash equivalents for the period was CNY 184,634,896.20, compared to a decrease of CNY -85,883,388.58 in the previous period[140] - Cash inflow from operating activities totaled CNY 212,983,559.20, compared to CNY 173,196,854.65 in the prior period, marking a growth of 23%[139] Investment and Development - The company has established a new subsidiary, Shanghai Iwu Stem Cell Technology Co., Ltd., with a registered capital of 150 million yuan, focusing on anti-aging and regenerative medicine[29] - The company is conducting clinical trials for five new allergen treatment products, including a Phase III trial for Artemisia annua powder drops[1] - Research and development expenses amounted to CNY 11.90 million, a slight decrease of 1.63% from the previous year[40] - The company has invested CNY 150 million in a new subsidiary focused on biopharmaceuticals[50] Market and Product Risks - The main product, "Dust Mite Drops," remains a significant revenue source, posing a risk due to product concentration[6] - The company faces risks in new drug development, including long cycles and high investment, which may affect future performance[7] - The company faces industry policy risks due to ongoing healthcare reforms, which may impact drug sales and production operations[66] - The trend of drug price reductions poses a risk to the company's performance, leading to potential sales abandonment in certain regions[67] Shareholder and Corporate Governance - The company plans to not distribute cash dividends or issue bonus shares[9] - The attendance rate for the 2017 annual general meeting was 54.03%[70] - The company has fulfilled its commitments regarding share transfer restrictions during the reporting period[72] - The company has made commitments to avoid competition and related transactions as detailed in its prospectus[73] Compliance and Reporting - The company’s financial statements are prepared in accordance with the accounting standards issued by the Ministry of Finance, ensuring compliance and transparency in financial reporting[162] - The financial report for the half-year period was not audited[117] - The company has not experienced any bankruptcy reorganization-related matters during the reporting period[77] Future Outlook - The company plans to expand its market presence and invest in new product development in the upcoming quarters[146] - Future guidance suggests a cautious outlook, with expected revenue growth of approximately 10% in the next fiscal year[146]

Financial Performance - The total operating revenue for the reporting period reached ¥218,709,503.59, representing a 32.44% increase compared to ¥165,132,855.77 in the same period last year[22]. - The net profit attributable to shareholders of the listed company was ¥103,940,262.61, up 32.02% from ¥78,730,064.47 year-on-year[22]. - The net profit after deducting non-recurring gains and losses was ¥99,102,541.29, reflecting a 33.02% increase from ¥74,501,661.44 in the previous year[22]. - The basic earnings per share increased to ¥0.3573, a rise of 31.99% from ¥0.2707 in the same period last year[22]. - Operating profit reached 121.61 million yuan, reflecting a growth of 32.42% compared to the previous year[30]. - The company achieved operating revenue of 218.71 million yuan, a year-on-year increase of 32.44%[30]. - The total comprehensive income for the period was CNY 103,942,914.18, compared to CNY 78,719,694.31 in the previous year, indicating a growth of 32.0%[121]. Assets and Liabilities - The total assets at the end of the reporting period were ¥891,041,645.90, which is a 5.04% increase from ¥848,311,200.92 at the end of the previous year[22]. - The net assets attributable to shareholders of the listed company increased to ¥840,560,844.06, up 4.91% from ¥801,257,929.88 at the end of the previous year[22]. - Total liabilities increased to ¥50,480,801.84 from ¥47,053,271.04, which is a rise of 5.2%[112]. - The company’s total assets included CNY 369.14 million in cash, representing 41.43% of total assets, an increase from 21.90% in the previous year[46]. Investment and R&D - The company is engaged in the development of new drugs for allergic diseases, which involves long and costly processes with unpredictable factors[8]. - The company is conducting clinical trials for five new allergen treatment products, including a Phase III trial for Artemisia annua powder drops[1]. - Research and development expenses amounted to CNY 11.90 million, a slight decrease of 1.63% from the previous year[40]. - The company is committed to continuous R&D investment and technology accumulation to maintain its competitive edge in the pharmaceutical industry[32]. Market and Product Development - The company’s main product, the dust mite drop, is the only standardized sublingual desensitization drug available in China, with a leading market share since 2012[32]. - The company has established a new subsidiary, Shanghai Iwu Stem Cell Technology Co., Ltd., with a registered capital of 150 million yuan, focusing on anti-aging and regenerative medicine[30]. - The company’s products are now available in over 30 provinces, cities, and autonomous regions across China, expanding its patient base significantly[30]. - The marketing strategy includes academic promotion and a professional academic marketing team to enhance product awareness among doctors and patients[34]. Risks and Challenges - The company faces risks related to high product gross margins and concentration on leading products, which may affect sustained performance growth[6]. - The company anticipates potential risks in the pharmaceutical industry due to ongoing policy reforms and price reductions, which may impact sales performance[56]. - The main product, "Dust Mite Drops," constitutes a significant portion of revenue, indicating a risk of revenue concentration[58]. - The company is actively pursuing new drug development, which involves lengthy and costly processes, presenting various risks[58]. Shareholder and Equity Information - The company plans not to distribute cash dividends, issue bonus shares, or increase share capital from reserves[9]. - The company did not distribute cash dividends or issue new shares during the half-year period[62]. - The total number of common shareholders at the end of the reporting period was 9,998[94]. - Zhejiang WoWu Management Consulting Co., Ltd. holds 38.86% of shares, totaling 113,030,073 shares, with 26,262,000 shares pledged[94]. Compliance and Governance - The half-year financial report has not been audited[67]. - The company has made commitments to ensure the accuracy and completeness of the prospectus, with penalties for any violations[66]. - The company has not reported any violations of commitments related to stock price stabilization plans[66]. - The company has not experienced any violations of commitments regarding related party transactions and capital occupation[65]. Future Outlook - Future guidance indicates a cautious outlook due to market volatility but aims for steady growth in revenue and profitability[138]. - The company plans to enhance its market expansion strategies and invest in new product development to drive future growth[138]. - The management highlighted the importance of innovation in product development to maintain competitive advantage in the biotechnology sector[138].

Financial Performance - Total revenue for Q1 2018 reached ¥106,934,012.73, representing a 31.86% increase compared to ¥81,099,600.17 in the same period last year[9] - Net profit attributable to shareholders was ¥51,954,370.06, up 35.98% from ¥38,207,667.31 year-on-year[9] - Basic earnings per share rose to ¥0.32, reflecting a 33.33% increase from ¥0.24 in the same quarter last year[9] - The company's operating revenue for the reporting period reached CNY 106,934,012.73, an increase of 31.86% compared to the same period last year[24] - The net profit attributable to shareholders of the listed company was CNY 51,954,370.06, reflecting a growth of 35.98% year-on-year[24] - The company reported a total profit of ¥61,152,518.92, up from ¥45,135,230.51, which is a growth of about 35.5% year-over-year[44] - The comprehensive income for the quarter was ¥51,941,157.54, compared to ¥38,205,045.61 in the previous year, indicating a growth of approximately 36%[45] Cash Flow and Liquidity - Net cash flow from operating activities increased by 48.83% to ¥57,417,598.08, compared to ¥38,578,340.29 in the previous year[9] - Cash and cash equivalents increased by CNY 96,987,816.69, a significant rise of 762.95% compared to the previous year, primarily due to increased cash from sales and the redemption of bank financial products[23] - The company's monetary funds at the end of the reporting period increased by CNY 84,275,537.55, up 45.35% from the beginning of the year, mainly due to the redemption of bank financial products[21] - The cash inflow from operating activities totaled CNY 112,178,784.29, an increase of 29.3% compared to CNY 86,722,895.10 in the previous period[51] - The cash inflow from sales of goods and services was CNY 111,284,662.25, up from CNY 85,879,072.93, marking a growth of 29.3%[51] - The company experienced a net increase in cash and cash equivalents of CNY 84,275,537.55, contrasting with a decrease of CNY 12,712,279.14 in the previous year[52] Assets and Liabilities - Total assets at the end of the reporting period were ¥903,274,521.54, a 6.48% increase from ¥848,311,200.92 at the end of the previous year[9] - The total current liabilities increased to CNY 45,222,234.12 from CNY 42,200,071.04, which is an increase of about 7.2%[37] - The total liabilities increased to ¥49,313,624.72 from ¥47,252,091.52, indicating a growth of approximately 4%[44] - The total equity attributable to the owners of the parent company reached CNY 853,199,087.42, up from CNY 801,257,929.88, marking an increase of approximately 6.5%[38] Risks and Challenges - The company faces industry policy risks due to ongoing healthcare reforms, which may impact drug sales and production operations[11] - Price reduction risks from bidding processes are a concern, potentially affecting the company's long-term sales strategy[11] Product Development and Market Strategy - The company is focused on expanding its product line and has several products in clinical trials, although the concentration on a few main products poses risks[12] - The company plans to leverage its academic marketing team to enhance product promotion, capitalizing on the growing demand in the desensitization treatment market[24] - The company is in the III phase of clinical trials for the Artemisia annua powder drops, aimed at treating allergic rhinitis and asthma caused by Artemisia pollen allergies, which will enhance product lines and market competitiveness[25] - The company has received approval for the clinical trial of the dust mite skin prick diagnostic kit, which will assist in diagnosing type I hypersensitivity diseases caused by dust mites, thereby enriching the product line and improving market competitiveness[26] - The company is conducting II phase clinical trials for the dust mite compound, which targets allergic rhinitis and asthma, aiming to enhance its product offerings and market position[25] - The company has received clinical trial approval for nine related prick test products, which will meet the allergen detection needs of more patients with allergic diseases[26] - The company is in the preclinical research phase for a silk protein moisturizing and anti-itch dressing, aimed at treating dry skin itching, which will diversify its product offerings[25] Shareholder Information - The top shareholder, Zhejiang Wo Wu Management Consulting Co., Ltd., holds 38.86% of the shares, indicating significant ownership concentration[14] - The company distributed cash dividends of RMB 4.00 per 10 shares, totaling RMB 64.64 million, and increased its share capital by 129.28 million shares through capital reserves, raising total shares to 290.88 million[29] - The company has not adjusted its cash dividend policy during the reporting period, ensuring the protection of minority shareholders' rights[29] Supplier and Customer Concentration - The top five suppliers accounted for 56.31% of total purchases in the current reporting period, up from 48.59% in the same period last year, indicating increased supplier concentration[27] - The top five customers contributed 51.20% of total sales in the current reporting period, down from 58.25% in the previous year, reflecting a decrease in customer concentration[27] Miscellaneous - The company has not reported any significant signed orders or progress during the reporting period[24] - The company has not made significant changes to its intangible assets or core technology team during the reporting period[26] - The company reported no non-operating fund occupation by controlling shareholders or related parties during the reporting period[31] - There were no violations regarding external guarantees during the reporting period[30] - The company did not conduct an audit for the first quarter report[56]

Financial Performance - The company's operating revenue for 2017 was CNY 385,576,841.66, representing a 23.55% increase compared to CNY 312,085,773.20 in 2016[18]. - The net profit attributable to shareholders for 2017 was CNY 186,103,945.40, a 44.04% increase from CNY 129,200,974.47 in 2016[18]. - The net cash flow from operating activities was CNY 159,134,139.23, up 29.62% from CNY 122,772,455.90 in 2016[18]. - Basic earnings per share for 2017 were CNY 1.15, a 43.75% increase from CNY 0.80 in 2016[18]. - Total assets at the end of 2017 were CNY 848,311,200.92, reflecting a 21.73% increase from CNY 696,894,623.78 at the end of 2016[18]. - The net assets attributable to shareholders increased by 22.22% to CNY 801,257,929.88 at the end of 2017 from CNY 655,576,730.37 at the end of 2016[18]. - The company reported a weighted average return on equity of 25.55% for 2017, up from 21.02% in 2016[18]. - The fourth quarter revenue was CNY 91,954,461.52, with a net profit of CNY 37,615,425.63 attributable to shareholders[20]. Research and Development - The company invested 24.19 million yuan in R&D, accounting for 6.27% of operating revenue[30]. - The company holds 12 valid domestic invention patents and has applied for 4 additional domestic invention patents[30]. - Research and development expenses increased by 35.60% to CNY 241.85 million, driven by projects like the "Artemisia annua powder drops"[34]. - The "Artemisia annua powder drops" completed Phase II clinical trials and is progressing well into Phase III trials[34]. - The company is preparing for clinical trials for nine new products related to allergen testing, enhancing its product line and market competitiveness[36]. Market and Sales - The sales network has expanded to cover over 30 provinces, cities, and autonomous regions in China[26]. - The company’s main product, the dust mite drop, maintains the highest market share in the dust mite desensitization drug market since 2012[29]. - The company’s revenue from the southern region increased by 30.33% to CNY 153.06 million[41]. - Sales volume of dust mite drops increased by 23.95% year-on-year, totaling 4,298,187 units sold[45]. - The total revenue from the pharmaceutical manufacturing segment was CNY 381.91 million, accounting for 99.05% of total revenue[41]. Investment and Financial Management - The company invested CNY 13 million in Shanghai Kaiyi Pharmaceutical Technology Co., holding a 19.9% stake to develop a new bronchodilator[34]. - The company reported a net decrease in cash and cash equivalents of ¥49,659,708.16, a decline of 36.68% year-on-year[54]. - The company’s total cash flow from investment activities was negative ¥168,360,243.36, a decline of 64.14% compared to the previous year[54]. - The company has a remaining balance of ¥23,340,373.30 in its fundraising special account as of December 31, 2017, including bank interest[64]. - The company reported a total of 285.96 million yuan in raised funds, which will be permanently supplemented to working capital after terminating the "Marketing Network Expansion and Information Technology Construction Project" due to slower-than-expected progress[67]. Shareholder and Governance - The company plans to distribute a cash dividend of CNY 4.00 per 10 shares, with a capital reserve conversion of 8 shares for every 10 shares held[6]. - The company reported a cash dividend of RMB 4.00 per 10 shares, totaling RMB 64,640,000, based on a total share capital of 161,600,000 shares as of December 31, 2017[85]. - The company has a policy in place to limit the transfer of shares by major shareholders during their tenure, with specific percentages outlined[88]. - The company is focused on maintaining shareholder confidence through strict adherence to shareholding commitments and dividend policies[88]. - The company’s management will increase their stock holdings within 90 days after the controlling shareholder's stock purchase plan is completed[93]. Risks and Challenges - The company has identified risks related to industry policies, bidding price reductions, and product concentration, which are discussed in detail in the report[6]. - The company faces risks from industry policy changes, including public hospital reforms and drug procurement models, which may impact sales and production operations[74]. - The company acknowledges the risk of price reductions due to bidding and cost control measures, which may lead to the abandonment of sales in certain regions to maintain price stability[75]. - The company recognizes the long and uncertain development cycle of new drugs, which includes multiple stages from preclinical research to market approval, posing various risks[76]. Internal Control and Compliance - The company has established a comprehensive internal control system, with no major or important deficiencies reported in financial or non-financial reporting[174]. - The company’s financial statements received a standard unqualified audit opinion from Ernst & Young Huaming, reflecting fair presentation in accordance with accounting standards[179]. - The company strictly follows information disclosure regulations, ensuring timely and accurate communication with investors[161]. - The company has implemented a transparent performance evaluation and incentive mechanism for senior management, ensuring compliance with legal standards[160]. Employee and Management Structure - The total number of employees in the company is 718, with 491 in the parent company and 227 in major subsidiaries[149]. - The company has established a comprehensive training management mechanism to enhance employee skills and career development, conducting various training programs including onboarding and job training[152]. - The company’s management team includes professionals with backgrounds in research, engineering, and finance, enhancing its operational capabilities[141][142]. - The total remuneration for directors, supervisors, and senior management during the reporting period amounts to 369.66 million CNY[148].

Financial Performance - Revenue for the reporting period was CNY 128,489,524.37, representing a 22.31% increase year-on-year[9] - Net profit attributable to shareholders increased by 43.98% to CNY 69,758,455.30 compared to the same period last year[9] - Basic earnings per share rose by 44.00% to CNY 0.4317[9] - The weighted average return on net assets increased by 1.56% to 9.57% for the reporting period[9] - The net profit for the third quarter of 2017 reached CNY 69,758,455.30, compared to CNY 48,449,776.71 in the previous year, marking an increase of about 43.9%[38] - The total profit for the third quarter was CNY 82,235,953.24, compared to CNY 58,657,805.13 in the previous year, which is an increase of approximately 40.2%[38] - The basic and diluted earnings per share for the third quarter were both CNY 0.4317, up from CNY 0.2998 in the same period last year, representing an increase of about 43.9%[39] - The total comprehensive income for the third quarter was CNY 69,751,334.64, compared to CNY 48,452,272.35 in the previous year, reflecting an increase of approximately 43.9%[39] - The net profit for Q3 2017 reached CNY 148,488,519.77, representing a growth of 44.8% from CNY 102,579,185.40 in Q3 2016[47] - The total profit for Q3 2017 was CNY 175,080,072.00, which is a 43.0% increase compared to CNY 122,377,072.95 in Q3 2016[46] Assets and Liabilities - Total assets increased by 15.64% to CNY 805,912,927.01 compared to the end of the previous year[9] - The total liabilities increased to CNY 42,265,167.69 from CNY 41,317,893.41, indicating a rise of 2.3%[31] - Accounts receivable increased by 44,375,819.90 yuan, up 57.79%, due to increased sales revenue and corresponding credit sales[17] - Inventory rose by 6,368,587.74 yuan, up 45.36%, attributed to expanded sales scale and increased inventory reserves[17] - Cash and cash equivalents decreased to CNY 165,407,344.64 from CNY 222,835,118.91, a decline of 26%[33] - Cash and cash equivalents at the end of the period were CNY 165,407,344.64, down from CNY 221,171,518.96 at the end of the same period last year, a decrease of 25.2%[56] Cash Flow - Cash flow from operating activities for the year-to-date was CNY 118,117,953.32, up 29.64%[9] - Net cash flow from operating activities increased by 27,008,741.35 yuan, up 29.64%, primarily due to higher cash received from sales[20] - The cash flow from operating activities for Q3 2017 was CNY 118,117,953.32, an increase of 29.7% from CNY 91,109,211.97 in the same quarter last year[53] - The total cash inflow from operating activities was CNY 273,506,577.59, an increase of 20.5% from CNY 226,867,082.76 in Q3 2016[53] - Operating cash flow net amount for the third quarter was CNY 120,053,866.53, an increase of 29.3% compared to CNY 92,813,009.90 in the same period last year[55] - Total cash inflow from investment activities was CNY 646,649,177.99, significantly higher than CNY 272,956,561.89 in the previous year, marking an increase of 137.5%[55] - Cash outflow from investment activities totaled CNY 783,723,028.24, compared to CNY 351,637,520.25 in the same period last year, representing an increase of 123.3%[55] - The net cash flow from investment activities was -CNY 137,073,850.25, worsening from -CNY 78,680,958.36 year-over-year[55] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 9,360[13] - The largest shareholder, Zhejiang Wowo Management Consulting Co., Ltd., held 38.86% of the shares[13] Other Financial Metrics - The company reported non-recurring gains and losses totaling CNY 6,535,667.36 for the year-to-date[10] - Development expenses increased by 11,463,391.57 yuan, up 36.27%, due to ongoing R&D investments in projects like Artemisia annua extract[17] - Other income increased by 1,870,599.22 yuan, a rise of 397.78%, primarily due to increased government subsidies received[19] - Investment income increased by 3,469,208.91 yuan, a growth of 169.46%, mainly from increased purchases of bank wealth management products[19] - The asset impairment loss for the third quarter was CNY 2,025,845.05, compared to CNY 1,696,376.82 in the previous year, indicating an increase of about 19.4%[38] - The investment income for the third quarter was CNY 2,473,546.13, significantly higher than CNY 264,904.11 in the previous year, marking an increase of approximately 834.5%[38] Reporting and Audit - The company did not conduct an audit for the third quarter report[57] - The report was released on October 26, 2017, by the legal representative Hu Gengxi[58]